GutHeart: Targeting Gut Microbiota to Treat Heart Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02637167|
Recruitment Status : Recruiting
First Posted : December 22, 2015
Last Update Posted : March 26, 2019
|Condition or disease||Intervention/treatment||Phase|
|Systolic Heart Failure||Drug: Rifaximin Drug: Saccharomyces boulardii||Phase 2|
While most studies on inflammation in heart failure (HF) have focused on down-stream mediators of inflammation and tissue damage, the present study will focus on alterations of the gut microbiota as a potential upstream arm in the activation of inflammatory responses. The gut microbiota may play a central role not only in the inflammatory arm of the pathogenesis of HF, but could also be involved in the induction of metabolic disturbances that contribute to the progression of this disorder. Decompensated HF is characterized by decreased cardiac output and congestion, contributing to edema and ischemia of the gut wall. Consequently, structural and functional changes occur, causing increased gut permeability.
Several studies have shown that low grade leakage of microbial products such as lipopolysaccharides (LPS), occurs across the gut wall, potentially causing systemic inflammation by activation of Toll like receptors (TLRs). Very small amounts of LPS have been shown to effectively induce release of TNFα 6, which acts as a cardiosuppressor via several pathways, including reduced mitochondrial activity, altered calcium homeostasis and impaired β-adrenergic signaling in cardiomyocytes. Furthermore, the investigators have recently shown that the microbiota-dependent marker TMAO is associated with clinical outcome in chronic HF. Interestingly, gut decontamination with antibiotics have been shown to reduce intestinal LPS-levels, monocyte expression of the LPS-receptor CD14 and production of TNFα. In addition, selective gut decontamination has improved postoperative outcome in cardiac surgery patients. However, at present there are no studies that have fully characterized the gut microbiota in HF patients and our knowledge of the interaction between gut microbiota, systemic inflammatory, metabolic disturbances and myocardial dysfunction in these patients are scarce.
This project will focus on the gut microbiota as a potential therapeutic target in HF, through an open label randomized controlled trial (RCT) of probiotics, antibiotics and controls, with improved heart function as primary end point.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||GutHeart: Targeting Gut Microbiota to Treat Heart Failure|
|Study Start Date :||March 11, 2016|
|Estimated Primary Completion Date :||June 20, 2019|
|Estimated Study Completion Date :||December 31, 2019|
Active Comparator: Rifaximin
Rifaximin: one tablet (550 mg) morning and evening for three months
Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
Other Name: Xifaxan
Active Comparator: Saccharomyces boulardii
S. boulardii: two capsules (500 mg) morning and evening for three months
Drug: Saccharomyces boulardii
The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
Other Name: Precosa
No Intervention: Control group
The third group receives no intervention
- baseline-adjusted LVEF as measured by echocardiography [ Time Frame: after 3 months of intervention ]A General Electrics Healthcare Vivid E9 Doppler ultrasound scanner or a similar, top specified cardiac ultrasound device will be used for echocardiographic imaging. Patients are examined in the lateral recumbent position after > 5 minutes of rest at baseline, prior to the start of study drug treatment, and at follow-up after 3 months, prior to study drug discontinuation. The heart is visualized by the standard ultrasonic techniques and imaging planes as recommended by the European society of echocardiography20,21 providing a comprehensive hemodynamic and valvular assessment.
- Chao1 (index) [ Time Frame: at baseline ]It will be analyzed by sequencing of 16s ribosomal RNA gene (Illumina chemistry)
- Chao1 (index) [ Time Frame: after 3 months ]It will be analyzed by sequencing of 16s ribosomal RNA gene (Illumina chemistry)
- Chao1 (index) [ Time Frame: after 6 months ]It will be analyzed by sequencing of 16s ribosomal RNA gene (Illumina chemistry)
- TMAO [ Time Frame: at baseline ]
- TMAO [ Time Frame: after 3 months ]
- Left ventricular end diastolic volume [ Time Frame: at baseline ]
- Left ventricular end diastolic volume [ Time Frame: after 3 months ]
- CRP [ Time Frame: at baseline ]
- CRP [ Time Frame: after 3 months ]
- Health-related quality of life score [ Time Frame: at baseline and after 3 months ]measured by the Minnesota Living with Heart Failure Questionnaire
- Functional capacity [ Time Frame: at baseline and after 3 months ]6 minutes walk test
- Number of patients with adverse events (any event) [ Time Frame: at baseline, after 1 month, after 3 month and after 6 months ]
- Number of adverse events (any event) [ Time Frame: at baseline, after 1 month, after 3 month and after 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02637167
|Contact: Lars L Gullestad, MD, Prof.||email@example.com|
|Contact: Kaspar Broch, MDfirstname.lastname@example.org|
|Oslo University Hospital - Rikshospitalet||Recruiting|
|Oslo, Norway, 0372|
|Contact: Cristiane C Mayerhofer, MD +47 97880206 email@example.com|
|Principal Investigator:||Lars L Gullestad, MD, Prof||Oslo University Hospital|